STOCK TITAN
  1. Home
  2. News
  3. KZR

Kezar Life Sciences Inc - KZR STOCK NEWS

Welcome to our dedicated news page for Kezar Life Sciences (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kezar Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kezar Life Sciences's position in the market.

News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Kezar Life Sciences, Inc. granted an employee a nonqualified stock option to purchase 12,000 shares at $0.93 per share, vesting over four years. The option was given as an inducement award for joining the company, following Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
News
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) provided a business update, highlighting the progress of their zetomipzomib programs for autoimmune disorders. The PALIZADE Phase 2b trial for lupus nephritis and PORTOLA Phase 2a trial for autoimmune hepatitis are actively enrolling with topline data expected in 2025 and 2026. The KZR-261 dose escalation study is ongoing with a data update by year-end. Financially, the company reported $201.4 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
earnings
-
News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Kezar Life Sciences, Inc. granted an employee a nonqualified stock option to purchase 36,000 shares at $1.03 per share, vesting over four years. This award aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
News
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) CEO to participate in Cardiorenal Corporate Panel at TD Cowen 44th Annual Health Care Conference. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
-
News
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Rhea-AI Summary
Everest Medicines and Kezar Life Sciences receive approval for Phase 2b PALIZADE trial in China for zetomipzomib in lupus nephritis patients, marking a significant milestone in the development of novel autoimmune disease treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
none
-
News
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) CEO to participate in fireside chat at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences
News
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Kezar Life Sciences, Inc. (Nasdaq: KZR) extends cash runway through strategic restructuring and collaboration with Everest Medicines to develop and commercialize zetomipzomib in Asia. Christopher Kirk, Ph.D., appointed as Chief Executive Officer. Financial results show $218.2 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
earnings
-
News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Kezar Life Sciences, Inc. (Nasdaq: KZR) has granted a nonqualified stock option to an employee, allowing them to purchase 50,000 shares of common stock at an exercise price of $0.77 per share. The stock option was granted as an inducement award to the individual joining the company. It will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remaining shares vesting monthly thereafter, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Kezar Life Sciences grants employee stock option
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
none
News
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
Rhea-AI Summary
Kezar Life Sciences, Inc. announces strategic realignment to focus on clinical programs, reducing workforce by 41% and extending cash runway to late 2026. Co-Founder Christopher Kirk appointed as CEO. Prioritizing clinical data readouts for zetomipzomib and KZR-261. Exploring strategic partnerships for protein secretion platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
management
Stock KZR logo
Kezar Life Sciences Inc

Nasdaq:KZR

KZR Rankings

#4626 Ranked by Market Cap
#5461 Ranked by Stock Gains
N/A Ranked by Dividends

KZR Stock Data

62.81M
52.50M
14.81%
67.93%
4.9%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About KZR

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.